QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Locuson, C. W. Articles by Jones, J. P. Search for Related Content PubMed PubMed Citation Articles by Locuson, C. W., II Articles by Jones, J. P.

ACCELERATED COMMUNICATION

A NEW CLASS OF CYP2C9 INHIBITORS: PROBING 2C9 SPECIFICITY WITH HIGH-AFFINITY BENZBROMARONE DERIVATIVES

Washington State University, School of Molecular Biosciences (C.W.L. II) and Department of Chemistry (De.A.R., Da.A.R., J.P.J.), Pullman, Washington; and Camitro Corp., Redwood City, California (J.L.W.)

Abstract

Noncovalent forces, other than hydrophobic interactions, are important determinants of substrate bias exhibited by some cytochromes P450. The CYP2C9 pharmacophore is proposed to include either an anionic group or hydrogen bond donor in addition to its hydrophobic groups. By constructing analogs of benzbromarone, evidence supporting the existence of a 2C9 anion-binding site was revealed. A nonsubstituted phenol analog was determined to have a pK_a of 8.4 and a K_i of 414 nM whereas those with dihalogenated benzoyl phenols had pK_a values between 4.2 to 5.2 and K_i values as low as 1 nM. The nonhalogenated, nonionizable analog is the poorest binder at 796 nM. The K_i range covers around three orders of magnitude with even the weakest binder being a more potent inhibitor than 2C9 substrate phenytoin. Thus, benzbromarone derivatives represent a class of molecules with the potential to reveal more structural details of the 2C9 active site.

This article has been cited by other articles:

				M. A. Hummel, T. S. Tracy, J. M. Hutzler, J. L. Wahlstrom, Y. Zhou, and D. A. Rock Influence of Fluorescent Probe Size and Cytochrome b5 on Drug-Drug Interactions in CYP2C9 J Biomol Screen, April 1, 2006; 11(3): 303 - 309. [Abstract] [PDF]

				M. A. Hummel, C. W. Locuson, P. M. Gannett, D. A. Rock, C. M. Mosher, A. E. Rettie, and T. S. Tracy CYP2C9 Genotype-Dependent Effects on in Vitro Drug-Drug Interactions: Switching of Benzbromarone Effect from Inhibition to Activation in the CYP2C9.3 Variant Mol. Pharmacol., September 1, 2005; 68(3): 644 - 651. [Abstract] [Full Text] [PDF]

				C. W. Locuson and J. L. Wahlstrom THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF CYTOCHROMES P450: EFFECT OF INCORPORATING HIGHER-AFFINITY LIGANDS AND POTENTIAL NEW APPLICATIONS Drug Metab. Dispos., July 1, 2005; 33(7): 873 - 878. [Abstract] [Full Text] [PDF]

				L. J. Dickmann, C. W. Locuson, J. P. Jones, and A. E. Rettie Differential Roles of Arg97, Asp293, and Arg108 in Enzyme Stability and Substrate Specificity of CYP2C9 Mol. Pharmacol., April 1, 2004; 65(4): 842 - 850. [Abstract] [Full Text]

				T. S. Dowers, D. A. Rock, D. A. Rock, B. N. S. Perkins, and J. P. Jones AN ANALYSIS OF THE REGIOSELECTIVITY OF AROMATIC HYDROXYLATION AND N-OXYGENATION BY CYTOCHROME P450 ENZYMES Drug Metab. Dispos., March 1, 2004; 32(3): 328 - 332. [Abstract] [Full Text] [PDF]

				A.-C. Egnell, C. Eriksson, N. Albertson, B. Houston, and S. Boyer Generation and Evaluation of a CYP2C9 Heteroactivation Pharmacophore J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 878 - 887. [Abstract] [Full Text] [PDF]